首页 > 最新文献

Research and Reports in Urology最新文献

英文 中文
The Use of Prophylactic Ureteric Stents in Major Abdomino-Pelvic Sarcoma Surgery: Risks, Benefits, and Potential Complications 在腹盆腔肉瘤大手术中使用预防性输尿管支架:风险、益处和潜在并发症
IF 1.6 Q3 Medicine Pub Date : 2023-12-01 DOI: 10.2147/rru.s435959
Mitchell Barns, Matthew Chau, Patrick Teloken, Rupert Hodder
{"title":"The Use of Prophylactic Ureteric Stents in Major Abdomino-Pelvic Sarcoma Surgery: Risks, Benefits, and Potential Complications","authors":"Mitchell Barns, Matthew Chau, Patrick Teloken, Rupert Hodder","doi":"10.2147/rru.s435959","DOIUrl":"https://doi.org/10.2147/rru.s435959","url":null,"abstract":"","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139016723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities. 局部到转移性前列腺癌转移和治疗机会的机制见解。
IF 2 Q2 UROLOGY & NEPHROLOGY Pub Date : 2023-11-29 eCollection Date: 2023-01-01 DOI: 10.2147/RRU.S386517
Eun-Mi Yu, Min Woo Hwang, Jeanny B Aragon-Ching

Prostate cancer is the most common non-cutaneous cancer among American men. Multiple mechanisms are involved in tumorigenesis and progression to metastases. While androgen deprivation therapy remains the cornerstone of treatment, progression to castration-resistant disease becomes inevitable. Aberrant pathway activations of PI3K/AKT due to PTEN loss, epithelial-mesenchymal transition pathways, homologous recombination repair, and DNA repair pathway mechanisms of resistance and cross-talk lead to opportunities for therapeutic targeting in metastatic castration-resistant prostate cancer. This review focuses on mechanisms of progression and key trials that evaluate the drugs and combinations that exploit these pathways.

前列腺癌是美国男性中最常见的非皮肤癌症。多种机制参与肿瘤的发生和发展到转移。虽然雄激素剥夺疗法仍然是治疗的基石,但不可避免地会发展为去势抵抗性疾病。PTEN缺失导致的PI3K/AKT异常通路激活、上皮-间质转化通路、同源重组修复和DNA修复通路的耐药和串话机制为转移性去势抵抗性前列腺癌的靶向治疗提供了机会。这篇综述的重点是进展机制和评估利用这些途径的药物和组合的关键试验。
{"title":"Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities.","authors":"Eun-Mi Yu, Min Woo Hwang, Jeanny B Aragon-Ching","doi":"10.2147/RRU.S386517","DOIUrl":"10.2147/RRU.S386517","url":null,"abstract":"<p><p>Prostate cancer is the most common non-cutaneous cancer among American men. Multiple mechanisms are involved in tumorigenesis and progression to metastases. While androgen deprivation therapy remains the cornerstone of treatment, progression to castration-resistant disease becomes inevitable. Aberrant pathway activations of PI3K/AKT due to PTEN loss, epithelial-mesenchymal transition pathways, homologous recombination repair, and DNA repair pathway mechanisms of resistance and cross-talk lead to opportunities for therapeutic targeting in metastatic castration-resistant prostate cancer. This review focuses on mechanisms of progression and key trials that evaluate the drugs and combinations that exploit these pathways.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138482912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refractory Bladder Neck Contracture (BNC) After Radical Prostatectomy: Prevalence, Impact and Management Challenges. 根治性前列腺切除术后难治性膀胱颈挛缩(BNC):患病率、影响和管理挑战。
IF 1.6 Q3 Medicine Pub Date : 2023-11-07 eCollection Date: 2023-01-01 DOI: 10.2147/RRU.S350777
Sabine Uguzova, Christian Beisland, Alfred Honoré, Patrick Juliebø-Jones

Bladder neck contracture is a recognised complication associated with radical prostatectomy. The management can be challenging, especially when refractory to initial intervention strategies. For the patient, the burden of disease is high and continence status cannot be overlooked. This review serves to provide an overview of the management of this recognised clinical pathology. Consideration needs to be given to minimally invasive approaches such as endoscopic incision, injectables, implantable devices as well as major reconstructive surgery where the condition persists. For the latter, this can involve open and robotic surgery as well as use of grafts and artificial sphincter surgery. These elements underline the need for a tailored and a patient centred approach.

膀胱颈挛缩是根治性前列腺切除术后常见的并发症。管理可能是具有挑战性的,特别是当最初的干预策略难以奏效时。对于患者而言,疾病负担高,尿失禁状况不容忽视。这篇综述提供了这一公认的临床病理管理的概述。需要考虑微创方法,如内镜切口、注射、植入式装置以及病情持续的重大重建手术。对于后者,这可以包括开放和机器人手术,以及使用移植物和人工括约肌手术。这些因素强调需要有针对性地采取以病人为中心的方法。
{"title":"Refractory Bladder Neck Contracture (BNC) After Radical Prostatectomy: Prevalence, Impact and Management Challenges.","authors":"Sabine Uguzova, Christian Beisland, Alfred Honoré, Patrick Juliebø-Jones","doi":"10.2147/RRU.S350777","DOIUrl":"10.2147/RRU.S350777","url":null,"abstract":"<p><p>Bladder neck contracture is a recognised complication associated with radical prostatectomy. The management can be challenging, especially when refractory to initial intervention strategies. For the patient, the burden of disease is high and continence status cannot be overlooked. This review serves to provide an overview of the management of this recognised clinical pathology. Consideration needs to be given to minimally invasive approaches such as endoscopic incision, injectables, implantable devices as well as major reconstructive surgery where the condition persists. For the latter, this can involve open and robotic surgery as well as use of grafts and artificial sphincter surgery. These elements underline the need for a tailored and a patient centred approach.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89719375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review 转移性去势敏感前列腺癌的治疗前景综述
Q3 Medicine Pub Date : 2023-11-01 DOI: 10.2147/rru.s398129
Margaret Meagher, Amirali Salmasi, Tyler Stewart
Abstract: With the advent of new therapeutic modalities, management of metastatic castrate-sensitive prostate cancer (mCSPC) has been in flux. From androgen-deprivation therapy to docetaxel to androgen receptor–signaling inhibitors, each agent has heralded a new treatment paradigm. As such, the optimal first-line therapy for mCSPC remains incompletely defined. This review provides a narrative of recent advances to systemic therapy within the mCSPC treatment space, particularly with regard to expansion to triplet therapy. Keywords: metastatic, castrate-sensitive prostate cancer, darolutamide
摘要:随着新的治疗方式的出现,转移性去势敏感前列腺癌(mCSPC)的治疗一直在不断变化。从雄激素剥夺疗法到多西他赛再到雄激素受体信号抑制剂,每种药物都预示着一种新的治疗模式。因此,mCSPC的最佳一线治疗仍未完全确定。本文综述了mCSPC治疗领域中系统性治疗的最新进展,特别是扩展到三联疗法。关键词:转移性,去势敏感前列腺癌,达罗他胺
{"title":"Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review","authors":"Margaret Meagher, Amirali Salmasi, Tyler Stewart","doi":"10.2147/rru.s398129","DOIUrl":"https://doi.org/10.2147/rru.s398129","url":null,"abstract":"Abstract: With the advent of new therapeutic modalities, management of metastatic castrate-sensitive prostate cancer (mCSPC) has been in flux. From androgen-deprivation therapy to docetaxel to androgen receptor–signaling inhibitors, each agent has heralded a new treatment paradigm. As such, the optimal first-line therapy for mCSPC remains incompletely defined. This review provides a narrative of recent advances to systemic therapy within the mCSPC treatment space, particularly with regard to expansion to triplet therapy. Keywords: metastatic, castrate-sensitive prostate cancer, darolutamide","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135714725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytoplasmic Androgen Receptor, CD24 Expression and Smoking Intensity to Urothelial Carcinoma of the Bladder Invasiveness: A Cross-Sectional Study. 细胞质雄激素受体、CD24表达和吸烟强度对膀胱浸润性尿路上皮癌的影响:一项横断面研究。
IF 1.6 Q3 Medicine Pub Date : 2023-11-01 eCollection Date: 2023-01-01 DOI: 10.2147/RRU.S433705
Sawkar Vijay Pramod, Ferry Safriadi, Bethy S Hernowo, Reiva Farah Dwiyana, Nurvita Trianasari, Shin Egawa

Purpose: To the best of our knowledge, Androgen receptor (AR) and cluster of differentiation 24 (CD24) expression in bladder urothelial carcinoma (UC) has not yet been reported in our population. The aim of this study was to evaluate the expression of both markers in UCB using immunohistochemistry.

Materials and methods: Data from 60 patients with UCB were obtained between 2009 and 2018. The samples were divided into four groups based on their smoking history. Group 1 included non-smokers, group 2 smoked <20 cigarettes/day for 30 years, group 3 smoked for 31-40 years, and group 4 smoked for > 40 years. Each group then divided into Non muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) subgroups. The smear was stained with hematoxylin and eosin (HE) - immunohistochemistry of CD24 and RA, followed by histoscore assessment.

Results: The male to female smoking rates was 1.8. Based on gender, in the NMIBC group there were 85.7% men and 14.3% were women while in MIBC 74.4% men and 25.6% women. The mean age of the NMIBC and MIBC groups was 56.3 years and 54.5 years, respectively. There was no significant relationship between smoking status in group 2 (OR 0.31, CI 95% CI, p=0,39), group 3 (OR 013, CI 95% CI, p=0,05), and group 4 (OR 0.23, CI 95% CI, p=0215) to the UCB invasiveness. A significant relationship was observed between cytoplasmic AR expression and UCB invasiveness (OR 0.14[0,04; 0.47], CI 95%, p=0.001). There was no significant relationship between RA in the nucleus and UCB invasion (OR 1.09[0,18; 6.48] CI 95%, p=1000). No significant relationship was observed between CD24 expression and UCB invasiveness (OR 0.81[0,27-2,45] CI 95%, p=0712).

Conclusion: Cytoplasmic AR expression is associated with UCB invasiveness. Smoking history and CD24 expression were not associated with UCB invasion.

目的:据我们所知,雄激素受体(AR)和分化簇24(CD24)在膀胱尿路上皮癌(UC)中的表达尚未在我们的人群中报道。本研究的目的是使用免疫组织化学方法评估两种标志物在UCB中的表达。材料和方法:2009年至2018年间,获得了60名UCB患者的数据。根据吸烟史将样本分为四组。第一组包括非吸烟者,第二组吸烟40年。然后将每组分为非肌肉浸润性膀胱癌症(NMIBC)和肌肉浸润性癌症(MIBC)亚组。涂片用苏木精和伊红(HE)-CD24和RA的免疫组织化学染色,然后进行组织评分评估。结果:男女吸烟率为1.8。根据性别,NMIBC组中有85.7%的男性和14.3%的女性,而MIBC组中有74.4%的男性和25.6%的女性。NMIBC组和MIBC组的平均年龄分别为56.3岁和54.5岁。第2组(OR 0.31,CI 95%CI,p=0,39)、第3组(OR 013,CI 95%置信区间,p=0,05)和第4组(OR 0.23,CI 95%可信区间,p=0215)的吸烟状态与UCB侵袭性之间没有显著关系。观察到细胞质AR表达与UCB侵袭性之间存在显著关系(OR 0.14[0,04;0.47],CI 95%,p=0.001)。细胞核中的RA与UCB浸润之间没有显著关系(OR1.09[0,18;6.48]CI 95%,p=1000)。CD24表达与UCB侵袭性无显著相关性(OR 0.81[0,27-2,45]CI 95%,p=0.012)。吸烟史和CD24表达与UCB侵袭无关。
{"title":"Cytoplasmic Androgen Receptor, CD24 Expression and Smoking Intensity to Urothelial Carcinoma of the Bladder Invasiveness: A Cross-Sectional Study.","authors":"Sawkar Vijay Pramod, Ferry Safriadi, Bethy S Hernowo, Reiva Farah Dwiyana, Nurvita Trianasari, Shin Egawa","doi":"10.2147/RRU.S433705","DOIUrl":"https://doi.org/10.2147/RRU.S433705","url":null,"abstract":"<p><strong>Purpose: </strong>To the best of our knowledge, Androgen receptor (AR) and cluster of differentiation 24 (CD24) expression in bladder urothelial carcinoma (UC) has not yet been reported in our population. The aim of this study was to evaluate the expression of both markers in UCB using immunohistochemistry.</p><p><strong>Materials and methods: </strong>Data from 60 patients with UCB were obtained between 2009 and 2018. The samples were divided into four groups based on their smoking history. Group 1 included non-smokers, group 2 smoked <20 cigarettes/day for 30 years, group 3 smoked for 31-40 years, and group 4 smoked for > 40 years. Each group then divided into Non muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) subgroups. The smear was stained with hematoxylin and eosin (HE) - immunohistochemistry of CD24 and RA, followed by histoscore assessment.</p><p><strong>Results: </strong>The male to female smoking rates was 1.8. Based on gender, in the NMIBC group there were 85.7% men and 14.3% were women while in MIBC 74.4% men and 25.6% women. The mean age of the NMIBC and MIBC groups was 56.3 years and 54.5 years, respectively. There was no significant relationship between smoking status in group 2 (OR 0.31, CI 95% CI, p=0,39), group 3 (OR 013, CI 95% CI, p=0,05), and group 4 (OR 0.23, CI 95% CI, p=0215) to the UCB invasiveness. A significant relationship was observed between cytoplasmic AR expression and UCB invasiveness (OR 0.14[0,04; 0.47], CI 95%, p=0.001). There was no significant relationship between RA in the nucleus and UCB invasion (OR 1.09[0,18; 6.48] CI 95%, p=1000). No significant relationship was observed between CD24 expression and UCB invasiveness (OR 0.81[0,27-2,45] CI 95%, p=0712).</p><p><strong>Conclusion: </strong>Cytoplasmic AR expression is associated with UCB invasiveness. Smoking history and CD24 expression were not associated with UCB invasion.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71485438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unilateral Testicular Infarction a Very Rare Complication of Genital Tuberculosis: A Case Report and Literature Review. 单侧睾丸梗死是生殖器结核的一种罕见并发症:病例报告和文献复习。
IF 1.6 Q3 Medicine Pub Date : 2023-10-31 eCollection Date: 2023-01-01 DOI: 10.2147/RRU.S434046
Feysel Hassen Issack, Nahom Tadesse Bogale, Samater Mohammed Hassen, Abdulhafiz Idris Ibrahim, Abdurehman Mohamed Abdi, Tariku Mulatu Bore, Isak Omer Answar

Background: Genitourinary tuberculosis is the second most common form of extrapulmonary tuberculosis in developing countries. Isolated genital TB is rare, but testicular infarction is an unusual complication of delayed management, in which surgical intervention is warranted.

Case presentation: A 29-year-old male non-smoker presents with painful left scrotal pain of 21 days. Initially managed with intravenous antibiotics, the disease progressed and resulted in testicular infarction. Left orchiectomy was performed, and the specimen was sent for histopathological examination, which revealed features consistent with a testicular tuberculous abscess.

Conclusion: Tuberculous epididymo-orchitis (TBEO) with testicular infarction was unusual. It is prudent to consider this in patients presenting with long-standing urinary symptoms, particularly in those unresponsive to the initial antibiotic therapy. It requires a high index of suspicion, especially in TB endemic areas.

背景:生殖道结核是发展中国家第二常见的肺外结核。孤立性生殖器结核是罕见的,但睾丸梗死是延迟治疗的一种不寻常并发症,需要手术干预。病例介绍:一名29岁男性,不吸烟,左阴囊疼痛21天。最初使用静脉注射抗生素治疗,病情进展并导致睾丸梗死。进行了左侧睾丸切除术,并将标本送去进行组织病理学检查,结果显示其特征与睾丸结核性脓肿一致。结论:结核性附睾睾丸炎(TBEO)合并睾丸梗死是不常见的。谨慎的做法是,在出现长期泌尿系统症状的患者中考虑这一点,尤其是那些对最初的抗生素治疗没有反应的患者。它需要很高的怀疑指数,尤其是在结核病流行地区。
{"title":"Unilateral Testicular Infarction a Very Rare Complication of Genital Tuberculosis: A Case Report and Literature Review.","authors":"Feysel Hassen Issack,&nbsp;Nahom Tadesse Bogale,&nbsp;Samater Mohammed Hassen,&nbsp;Abdulhafiz Idris Ibrahim,&nbsp;Abdurehman Mohamed Abdi,&nbsp;Tariku Mulatu Bore,&nbsp;Isak Omer Answar","doi":"10.2147/RRU.S434046","DOIUrl":"10.2147/RRU.S434046","url":null,"abstract":"<p><strong>Background: </strong>Genitourinary tuberculosis is the second most common form of extrapulmonary tuberculosis in developing countries. Isolated genital TB is rare, but testicular infarction is an unusual complication of delayed management, in which surgical intervention is warranted.</p><p><strong>Case presentation: </strong>A 29-year-old male non-smoker presents with painful left scrotal pain of 21 days. Initially managed with intravenous antibiotics, the disease progressed and resulted in testicular infarction. Left orchiectomy was performed, and the specimen was sent for histopathological examination, which revealed features consistent with a testicular tuberculous abscess.</p><p><strong>Conclusion: </strong>Tuberculous epididymo-orchitis (TBEO) with testicular infarction was unusual. It is prudent to consider this in patients presenting with long-standing urinary symptoms, particularly in those unresponsive to the initial antibiotic therapy. It requires a high index of suspicion, especially in TB endemic areas.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71426419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Robot-assisted Surgery in the Field of Urology: The Most Pioneering Approaches 2015-2023. 泌尿外科领域的机器人辅助手术:最具开拓性的方法2015-2023。
IF 2 Q2 UROLOGY & NEPHROLOGY Pub Date : 2023-10-09 eCollection Date: 2023-01-01 DOI: 10.2147/RRU.S386025
Antonio Franco, Francesco Ditonno, Celeste Manfredi, Andrew D Johnson, Avinash Mamgain, Oren Feldman-Schultz, Carol L Feng, Antony A Pellegrino, Maria Carmen Mir, Francesco Porpiglia, Simone Crivellaro, Cosimo De Nunzio, Alexander K Chow, Riccardo Autorino

Robot-assisted surgery has emerged as a transformative technology, revolutionizing surgical approaches and techniques that decades ago could barely be imagined. The field of urology has taken charge in pioneering a new era of minimally invasive surgery with the ascent of robotic systems which offer enhanced visualization, precision, dexterity, and enabling surgeons to perform intricate maneuvers with improved accuracy. This has led to improved surgical outcomes, including reduced blood loss, lower complication rates, and faster patient recovery. The aim of our review is to present an evidence-based critical analysis on the most pioneering robotic urologic approaches described over the last eight years (2015-2023).

机器人辅助手术已经成为一项变革性技术,革命性地改变了几十年前难以想象的手术方法和技术。随着机器人系统的兴起,泌尿外科领域开创了微创手术的新时代,机器人系统提供了增强的可视化、精度和灵活性,并使外科医生能够以更高的精度进行复杂的操作。这导致了手术结果的改善,包括减少失血、降低并发症发生率和加快患者康复。我们综述的目的是对过去八年(2015-2023年)中描述的最具开创性的机器人泌尿外科方法进行循证批判性分析。
{"title":"Robot-assisted Surgery in the Field of Urology: The Most Pioneering Approaches 2015-2023.","authors":"Antonio Franco, Francesco Ditonno, Celeste Manfredi, Andrew D Johnson, Avinash Mamgain, Oren Feldman-Schultz, Carol L Feng, Antony A Pellegrino, Maria Carmen Mir, Francesco Porpiglia, Simone Crivellaro, Cosimo De Nunzio, Alexander K Chow, Riccardo Autorino","doi":"10.2147/RRU.S386025","DOIUrl":"10.2147/RRU.S386025","url":null,"abstract":"<p><p>Robot-assisted surgery has emerged as a transformative technology, revolutionizing surgical approaches and techniques that decades ago could barely be imagined. The field of urology has taken charge in pioneering a new era of minimally invasive surgery with the ascent of robotic systems which offer enhanced visualization, precision, dexterity, and enabling surgeons to perform intricate maneuvers with improved accuracy. This has led to improved surgical outcomes, including reduced blood loss, lower complication rates, and faster patient recovery. The aim of our review is to present an evidence-based critical analysis on the most pioneering robotic urologic approaches described over the last eight years (2015-2023).</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/b4/rru-15-453.PMC10575039.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41238110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progressing Towards Same-Day Discharges After Robotic-Assisted Radical Prostatectomy; Safe and Cost Effective to Discharge Without Routine Blood Tests. 机器人辅助前列腺癌根治术后当天出院的进展;无需常规血液检查即可安全且经济高效地出院。
IF 1.6 Q3 Medicine Pub Date : 2023-10-09 eCollection Date: 2023-01-01 DOI: 10.2147/RRU.S429819
Bodie Chislett, Ghadir Omran, Michael Harvey, Damien Bolton, Nathan Lawrentschuk

Introduction: Changing population demographics and the recent SARS-CoV-2 pandemic have forever changed healthcare, with increasing demands on straining systems. The economic cost is yet to be fully realised, with growing concerns around the current system's ability to accommodate the ageing comorbid population. Consequently, a paradigm shift has taken place in healthcare systems, prioritizing cost accountability. In the absence of established guidelines or robust literature, the use of laboratory tests postoperatively is often guided solely by clinician preference. This study presents a retrospective analysis that investigates the utility and cost implications of routine postoperative investigation following robotic-assisted radical prostatectomies. The findings aim to emphasise the importance of evidence-based practices and cost-effective approaches in postoperative care.

Materials/methods: A retrospective analysis was performed on all robotic-assisted radical prostatectomies (RARP) identified from a single institution between 29th June 2017 to 28th June 2019. This interval was chosen in an attempt to avoid bias or confounding variables associated with the SRS-CoV-2 pandemic. A single clinician conducted a comprehensive medical record review using unit record numbers corresponding to identified procedural codes. Demographics and variables were recorded, including postoperative test results, hospital length of stay and 30-day readmission rates. Patients were assigned to either 'Routine Postoperative tests' (RPOT) or 'No Routine Postoperative tests' (No RPOT) and a comparative analysis was performed. Using the Australian National Pharmaceutical Benefits Scheme (PBS) pricing guide, total expenditure was calculated.

Results: A total of 319 patients were included in the study with an average of 2.5 tests per patient within the first 24 hours. Routine postoperative tests had no bearing on outcomes, with comparable readmission rates between cohorts, and a significantly shorter length of stay in the "No routine postoperative tests" group when compared to the "Routine Postoperative Tests". A total of 1028 tests were performed within the first 48 hours following surgery with expenditure on routine testing totalling $20,516 based on the Australian PBS pricing schedule. Abnormal results were returned on 96% of patients. In the RPOT group, 18 out of the 20 common interventions occurred from 302 RARP. Among the patients in the RPOT group, eight individuals underwent blood transfusions. However, none of these patients met the hospital-specific criteria for transfusion, which require a hemoglobin level below 70 or symptomatic presentation with a hemoglobin level below 80.

Conclusion: The data suggests routine postoperative laboratory has no bearing on re-admission rates, with patients experiencing significantly shorter hospital stays. Furthermore, our results indicate ineff

引言:不断变化的人口结构和最近的严重急性呼吸系统综合征冠状病毒2型疫情永远改变了医疗保健,对紧张系统的需求越来越大。经济成本尚未完全实现,人们越来越担心当前系统适应老龄化共病人群的能力。因此,医疗保健系统发生了范式转变,优先考虑成本问责制。在缺乏既定指南或可靠文献的情况下,术后实验室测试的使用通常仅由临床医生的偏好指导。本研究提供了一项回顾性分析,调查机器人辅助前列腺根治术后常规术后调查的效用和成本影响。研究结果旨在强调循证实践和成本效益高的术后护理方法的重要性。材料/方法:对2017年6月29日至2019年6月28日期间从一家机构确定的所有机器人辅助前列腺根治术(RARP)进行回顾性分析。选择这一区间是为了避免与SRS-CoV-2大流行相关的偏见或混淆变量。一名临床医生使用与识别的程序代码相对应的单位记录编号进行了全面的医疗记录审查。记录人口统计学和变量,包括术后检查结果、住院时间和30天再次入院率。将患者分为“术后常规检查”(RPOT)或“无术后常规测试”(无RPOT),并进行比较分析。使用澳大利亚国家药品福利计划(PBS)定价指南,计算总支出。结果:共有319名患者被纳入研究,在前24小时内平均每位患者进行2.5次检测。常规术后检查与结果无关,队列之间的再入院率相当,与“常规术后测试”相比,“无常规术后检测”组的住院时间明显更短。在手术后的前48小时内,共进行了1028次检测,根据澳大利亚PBS定价表,常规检测支出总计20516美元。96%的患者出现异常结果。在RPOT组中,20种常见干预措施中有18种发生在302例RARP中。在RPOT组的患者中,有8人接受了输血。然而,这些患者都不符合医院特定的输血标准,即血红蛋白水平低于70或血红蛋白水平低于80的症状表现。结论:数据表明,常规术后实验室检查与再次入院率无关,患者住院时间明显缩短。此外,我们的研究结果表明,常规术后实验室的使用效率低下,临床干预措施很少,异常结果频繁,累积费用巨大。
{"title":"Progressing Towards Same-Day Discharges After Robotic-Assisted Radical Prostatectomy; Safe and Cost Effective to Discharge Without Routine Blood Tests.","authors":"Bodie Chislett,&nbsp;Ghadir Omran,&nbsp;Michael Harvey,&nbsp;Damien Bolton,&nbsp;Nathan Lawrentschuk","doi":"10.2147/RRU.S429819","DOIUrl":"10.2147/RRU.S429819","url":null,"abstract":"<p><strong>Introduction: </strong>Changing population demographics and the recent SARS-CoV-2 pandemic have forever changed healthcare, with increasing demands on straining systems. The economic cost is yet to be fully realised, with growing concerns around the current system's ability to accommodate the ageing comorbid population. Consequently, a paradigm shift has taken place in healthcare systems, prioritizing cost accountability. In the absence of established guidelines or robust literature, the use of laboratory tests postoperatively is often guided solely by clinician preference. This study presents a retrospective analysis that investigates the utility and cost implications of routine postoperative investigation following robotic-assisted radical prostatectomies. The findings aim to emphasise the importance of evidence-based practices and cost-effective approaches in postoperative care.</p><p><strong>Materials/methods: </strong>A retrospective analysis was performed on all robotic-assisted radical prostatectomies (RARP) identified from a single institution between 29th June 2017 to 28th June 2019. This interval was chosen in an attempt to avoid bias or confounding variables associated with the SRS-CoV-2 pandemic. A single clinician conducted a comprehensive medical record review using unit record numbers corresponding to identified procedural codes. Demographics and variables were recorded, including postoperative test results, hospital length of stay and 30-day readmission rates. Patients were assigned to either 'Routine Postoperative tests' (RPOT) or 'No Routine Postoperative tests' (No RPOT) and a comparative analysis was performed. Using the Australian National Pharmaceutical Benefits Scheme (PBS) pricing guide, total expenditure was calculated.</p><p><strong>Results: </strong>A total of 319 patients were included in the study with an average of 2.5 tests per patient within the first 24 hours. Routine postoperative tests had no bearing on outcomes, with comparable readmission rates between cohorts, and a significantly shorter length of stay in the \"No routine postoperative tests\" group when compared to the \"Routine Postoperative Tests\". A total of 1028 tests were performed within the first 48 hours following surgery with expenditure on routine testing totalling $20,516 based on the Australian PBS pricing schedule. Abnormal results were returned on 96% of patients. In the RPOT group, 18 out of the 20 common interventions occurred from 302 RARP. Among the patients in the RPOT group, eight individuals underwent blood transfusions. However, none of these patients met the hospital-specific criteria for transfusion, which require a hemoglobin level below 70 or symptomatic presentation with a hemoglobin level below 80.</p><p><strong>Conclusion: </strong>The data suggests routine postoperative laboratory has no bearing on re-admission rates, with patients experiencing significantly shorter hospital stays. Furthermore, our results indicate ineff","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/71/rru-15-471.PMC10575481.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41238109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epithelioid Angiomyolipoma with Tumor Thrombus into Inferior Vena Cava Presurgically Treated with Combination Therapy of Pembrolizumab and Axitinib: A Case Report. Pembrolizumab和Axitinib联合治疗肿瘤栓入下腔静脉的上皮样血管平滑肌脂肪瘤一例报告。
IF 1.6 Q3 Medicine Pub Date : 2023-10-05 eCollection Date: 2023-01-01 DOI: 10.2147/RRU.S425887
Chihiro Kawasoe, Yoshi Miyamoto, Kaoru Ito, Takaya Murashima, Takahiro Nagai, Hiroki Takamori, Takumi Kiwaki, Toshio Kamimura, Shoichiro Mukai, Toshiyuki Kamoto

Epithelioid angiomyolipoma (EAML) is a rare variant of AML with malignant potential. It is occasionally difficult to distinguish EAML from renal cell carcinoma (RCC) on imaging. A 72-year-old woman was admitted to our hospital for the treatment of a left renal tumor with relatively high blood flow and a tumor thrombus extending to the inferior vena cava, suggesting RCC. The patient underwent presurgical combination therapy with axitinib and pembrolizumab. This treatment significantly shortened the thrombus, and radical nephrectomy was performed. The pathological findings were compatible with EAML, and the treatment effects were observed. We report a case treated pre-surgically with a combined therapy of pembrolizumab and axitinib, with a favorable response as a treatment option for EAML.

上皮样血管平滑肌脂肪瘤(EAML)是一种罕见的AML变体,具有恶性潜能。在影像学上有时很难区分EAML和肾细胞癌(RCC)。一位72岁的女性因左肾肿瘤入院治疗,该肿瘤血流量相对较高,肿瘤血栓延伸至下腔静脉,提示肾细胞癌。患者在术前接受了阿西替尼和pembrolizumab的联合治疗。这种治疗显著缩短了血栓,并进行了根治性肾切除术。病理结果符合EAML,并观察治疗效果。我们报告了一例术前接受pembrolizumab和阿西替尼联合治疗的病例,作为EAML的治疗选择,疗效良好。
{"title":"Epithelioid Angiomyolipoma with Tumor Thrombus into Inferior Vena Cava Presurgically Treated with Combination Therapy of Pembrolizumab and Axitinib: A Case Report.","authors":"Chihiro Kawasoe,&nbsp;Yoshi Miyamoto,&nbsp;Kaoru Ito,&nbsp;Takaya Murashima,&nbsp;Takahiro Nagai,&nbsp;Hiroki Takamori,&nbsp;Takumi Kiwaki,&nbsp;Toshio Kamimura,&nbsp;Shoichiro Mukai,&nbsp;Toshiyuki Kamoto","doi":"10.2147/RRU.S425887","DOIUrl":"https://doi.org/10.2147/RRU.S425887","url":null,"abstract":"<p><p>Epithelioid angiomyolipoma (EAML) is a rare variant of AML with malignant potential. It is occasionally difficult to distinguish EAML from renal cell carcinoma (RCC) on imaging. A 72-year-old woman was admitted to our hospital for the treatment of a left renal tumor with relatively high blood flow and a tumor thrombus extending to the inferior vena cava, suggesting RCC. The patient underwent presurgical combination therapy with axitinib and pembrolizumab. This treatment significantly shortened the thrombus, and radical nephrectomy was performed. The pathological findings were compatible with EAML, and the treatment effects were observed. We report a case treated pre-surgically with a combined therapy of pembrolizumab and axitinib, with a favorable response as a treatment option for EAML.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b7/2c/rru-15-447.PMC10561617.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41210976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Diagnostic Performance of the LINEAR Cromatest and Laboquick URS 10-T Dipsticks Among Urinary Tract Infection Suspects in Addis Ababa, Ethiopia: A Cross-Sectional Study. 埃塞俄比亚亚的斯亚贝巴尿路感染疑似人群中线性Cromatest和Labosquick URS10-T滴剂诊断性能的评估:一项横断面研究。
IF 1.6 Q3 Medicine Pub Date : 2023-10-04 eCollection Date: 2023-01-01 DOI: 10.2147/RRU.S434128
Yosef Gebretensaie, Abay Atnafu, Yonas Alemu, Selfu Girma, Kassu Desta

Background: Urinary tract infections (UTIs) bring a significant and serious health-related problem. Repeated infections may lead to the development of renal scarring and end-stage renal dysfunction. Therefore, balancing the choices of UTI diagnostic tools depending on the costs versus accuracy can minimize false results that may subject patients to wrong treatments.

Objective: The objective of the study was to evaluate the diagnostic performance of LINEAR cromatest and Laboquick URS 10-T dipsticks against conventional urine culture at Arsho Advanced Medical Laboratory (AAML), Addis Ababa, Ethiopia.

Methods: A similar cohort of UTI-suspected patients from our previous study, who were prospectively enrolled from Arsho Advanced Medical Laboratory, Addis Ababa, Ethiopia, were considered for this analysis. Data analysis was performed using SPSS version 26. The sensitivity, specificity, and predictive value of different dipsticks were calculated using culture as a gold standard. ROC curve analysis was also used to determine diagnostic performance. A test with a P-value of <0.05 was considered statistically significant.

Results: Out of 446 urine samples processed, bacterial growth was observed in 141 (31.6%). Of this figure, 105/141 (74.5%) and 36/141 (25.5%) were from female and male participants, respectively. The sensitivity and specificity of the LINEAR Cromatest dipstick were 83.7% and 67.9%, respectively (P-value <0.001). The Laboquick URS 10-T dipstick showed sensitivity and specificity of 87.9% and 68.5%, respectively (P-value <0.001). The ROC analysis showed an AUC of >0.7 for both dipsticks.

Conclusion: In a setting where there is no access to urine culture, the urine dipstick may be considered an alternative diagnostic tool in the diagnosis of UTIs.

背景:尿路感染(UTIs)带来了一个重大而严重的健康问题。反复感染可能导致肾瘢痕形成和终末期肾功能障碍。因此,根据成本和准确性来平衡UTI诊断工具的选择,可以最大限度地减少可能使患者接受错误治疗的错误结果。目的:本研究旨在评估埃塞俄比亚亚的斯亚贝巴Arsho高级医学实验室(AAML)的线性色氨酸盐和Laboquick URS 10-T滴管对传统尿液培养的诊断性能。方法:我们之前的研究中有一个类似的UTI疑似患者队列,他们前瞻性地从埃塞俄比亚亚的斯亚贝巴的Arsho高级医学实验室招募,被考虑用于本分析。数据分析采用SPSS版本26。以培养物为金标准,计算不同滴管的敏感性、特异性和预测值。ROC曲线分析也用于确定诊断性能。P值为结果的测试:在处理的446个尿液样本中,141个样本(31.6%)观察到细菌生长。在这一数字中,105/141个样本(74.5%)和36/141个(25.5%)分别来自女性和男性参与者。LINERAL Cromatest试纸的敏感性和特异性分别为83.7%和67.9%(两种试纸的P值P值均为0.7)。结论:在无法进行尿液培养的情况下,尿液试纸可被视为诊断尿路感染的替代诊断工具。
{"title":"Evaluation of the Diagnostic Performance of the LINEAR Cromatest and Laboquick URS 10-T Dipsticks Among Urinary Tract Infection Suspects in Addis Ababa, Ethiopia: A Cross-Sectional Study.","authors":"Yosef Gebretensaie,&nbsp;Abay Atnafu,&nbsp;Yonas Alemu,&nbsp;Selfu Girma,&nbsp;Kassu Desta","doi":"10.2147/RRU.S434128","DOIUrl":"10.2147/RRU.S434128","url":null,"abstract":"<p><strong>Background: </strong>Urinary tract infections (UTIs) bring a significant and serious health-related problem. Repeated infections may lead to the development of renal scarring and end-stage renal dysfunction. Therefore, balancing the choices of UTI diagnostic tools depending on the costs versus accuracy can minimize false results that may subject patients to wrong treatments.</p><p><strong>Objective: </strong>The objective of the study was to evaluate the diagnostic performance of LINEAR cromatest and Laboquick URS 10-T dipsticks against conventional urine culture at Arsho Advanced Medical Laboratory (AAML), Addis Ababa, Ethiopia.</p><p><strong>Methods: </strong>A similar cohort of UTI-suspected patients from our previous study, who were prospectively enrolled from Arsho Advanced Medical Laboratory, Addis Ababa, Ethiopia, were considered for this analysis. Data analysis was performed using SPSS version 26. The sensitivity, specificity, and predictive value of different dipsticks were calculated using culture as a gold standard. ROC curve analysis was also used to determine diagnostic performance. A test with a P-value of <0.05 was considered statistically significant.</p><p><strong>Results: </strong>Out of 446 urine samples processed, bacterial growth was observed in 141 (31.6%). Of this figure, 105/141 (74.5%) and 36/141 (25.5%) were from female and male participants, respectively. The sensitivity and specificity of the LINEAR Cromatest dipstick were 83.7% and 67.9%, respectively (<i>P</i>-value <0.001). The Laboquick URS 10-T dipstick showed sensitivity and specificity of 87.9% and 68.5%, respectively (<i>P</i>-value <0.001). The ROC analysis showed an AUC of >0.7 for both dipsticks.</p><p><strong>Conclusion: </strong>In a setting where there is no access to urine culture, the urine dipstick may be considered an alternative diagnostic tool in the diagnosis of UTIs.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/ce/rru-15-437.PMC10560765.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41210977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Research and Reports in Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1